Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Gain Therapeutics, Inc. (GANX)

3.92   0.04 (1.03%) 06-26 18:39
Open: 3.9 Pre. Close: 3.88
High: 3.9799 Low: 3.76
Volume: 76,278 Market Cap: 47(M)
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.99 - 4 4 - 4.02
Low: 3.72 - 3.74 3.74 - 3.75
Close: 3.89 - 3.92 3.92 - 3.95

Technical analysis

as of: 2022-06-24 4:40:11 PM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 4.64     One year: 5.42
Support: Support1: 2.96    Support2: 2.32
Resistance: Resistance1: 3.97    Resistance2: 4.64
Pivot: 3.55
Moving Average: MA(5): 3.77     MA(20): 3.42
MA(100): 3.61     MA(250): 5.75
MACD: MACD(12,26): 0.1     Signal(9): 0.1
Stochastic oscillator: %K(14,3): 87.5     %D(3): 84.8
RSI: RSI(14): 63.1
52-week: High: 10.4  Low: 2.32
Average Vol(K): 3-Month: 171 (K)  10-Days: 78 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ GANX ] has closed below upper band by 11.4%. Bollinger Bands are 20.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Sat, 25 Jun 2022
Gain Therapeutics Presents Positive Preclinical Data on its Small Molecule Lead Compound in GBA1 Parkinson's Disease at XXVII IAPRD World Congress -

Wed, 15 Jun 2022
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update - Defense World

Thu, 02 Jun 2022
2022-06-02 | NDAQ:GANX | Press Release | Gain Therapeutics Inc. - Stockhouse

Fri, 27 May 2022
Gain Therapeutics, Inc. (NASDAQ:GANX) Sees Significant Growth in Short Interest - Defense World

Wed, 18 May 2022
Gain Therapeutics to Participate at the H.C. Wainwright Global Investment Conference - Yahoo Finance

Wed, 11 May 2022
Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program at IWGGD Symposium - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 12 (M)
% Held by Insiders 8.74e+006 (%)
% Held by Institutions 24.3 (%)
Shares Short 37 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.463e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -8
Return on Assets (ttm) 542.6
Return on Equity (ttm) -21.4
Qtrly Rev. Growth 171470
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.03
Qtrly Earnings Growth -1.3
Operating Cash Flow 0 (M)
Levered Free Cash Flow -12 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 477.19
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 78050
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.